Equity	12 Months Ended
Dec. 31, 2019
Equity [Abstract]
Equity	7. EQUITY Issuance of Additional Common Stock On May 18, 2017, the stockholders of the Company approved the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the “Amended and Restated 2012 Plan”) that increased the number of shares of the Company’s common stock that may be awarded under the Amended and Restated 2012 Plan by 600,000, to an aggregate of 1,600,000. Stock Repurchase Plan The Company implemented a stock repurchase plan on September 16, 2014 (the “Stock Repurchase Plan”). On September 12, 2019, the Company's Board of Directors authorized an additional 2,000,000 shares for repurchase under the Stock Repurchase Plan. The Company repurchased approximately 296,000 shares during the year ended December 31, 2019. As of December 31, 2019, there were approximately 2,369,000 shares of common stock remaining under the Company’s Stock Repurchase Plan. There is no guarantee as to the exact number of shares of the Company’s common stock, if any, that will be repurchased under the Stock Repurchase Plan. Stockholder Rights Plan On November 21, 2019, the Company adopted a limited duration stockholder rights plan (the “Rights Plan”), as amended on December 13, 2019, and declared a dividend of one right for each outstanding share of Medifast common stock. The Rights Plan expires on October 21, 2020, and the Board of Directors may terminate the Rights Plan at any time if it no longer believes that the Rights Plan is in the best interests of the Company and its stockholders. These rights are not presently exercisable and remain attached to the shares of common stock until the occurrence of certain triggering events.

Equity

12 Months Ended

Dec. 31, 2019

7. EQUITY

Issuance of Additional Common Stock

On May 18, 2017, the stockholders of the Company approved the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the “Amended and Restated 2012 Plan”) that increased the number of shares of the Company’s common stock that may be awarded under the Amended and Restated 2012 Plan by 600,000, to an aggregate of 1,600,000.

Stock Repurchase Plan

The Company implemented a stock repurchase plan on September 16, 2014 (the “Stock Repurchase Plan”). On September 12, 2019, the Company's Board of Directors authorized an additional 2,000,000 shares for repurchase under the Stock Repurchase Plan. The Company repurchased approximately 296,000 shares during the year ended December 31, 2019. As of December 31, 2019, there were approximately 2,369,000 shares of common stock remaining under the Company’s Stock Repurchase Plan. There is no guarantee as to the exact number of shares of the Company’s common stock, if any, that will be repurchased under the Stock Repurchase Plan.

Stockholder Rights Plan

On November 21, 2019, the Company adopted a limited duration stockholder rights plan (the “Rights Plan”), as amended on December 13, 2019, and declared a dividend of one right for each outstanding share of Medifast common stock. The Rights Plan expires on October 21, 2020, and the Board of Directors may terminate the Rights Plan at any time if it no longer believes that the Rights Plan is in the best interests of the Company and its stockholders. These rights are not presently exercisable and remain attached to the shares of common stock until the occurrence of certain triggering events.